The VinePair Podcast: Are GLP-1s Really Affecting the Alcohol Business?
Ozempic, Hims & Hers, Ro, Wegovy — there’s no shortage of Glucagon-Like Peptide-1 (GLP-1) drugs on the market right now. And unlike other weight loss supplements of years past, these GLP-1s are relatively easy to acquire. More often than not, a prospective customer takes a quiz, a doctor reviews the results, and a prescription arrives in the mail a few days later.
But on top of helping people lose weight, these supplements are said to curb cravings for indulgences like rich foods and alcoholic beverages. Do GLP-1s therefore pose a legitimate threat to the booze industry, or are they too expensive to have any substantial impact?
On this episode of the “VinePair Podcast,” Adam and Joanna discuss a topic that’s been bubbling up for some time: the impact of Ozempic and other GLP-1 drugs on the alcohol industry. As these drugs become easier to acquire and less stigmatized, are they having a noticeable effect on alcohol sales? Tune in for more.
Please remember to enter VinePair’s Best New Bartender Competition, presented by Luxardo. Submissions are due April 18th.
Joanna is reading: 8 Things We Learned From Trying 32 of NYC’s Best Martinis
Adam is reading: Champagne Sales Are Slumping. Is Prosecco to Blame?
Listen Online
The article The VinePair Podcast: Are GLP-1s Really Affecting the Alcohol Business? appeared first on VinePair.